AIMS: To describe the clinical outcome of three patients with Behçet's disease maintained on infliximab who were switched to adalimumab therapy. METHODS: Case note review. Main outcome measure was recurrence of uveitis. RESULTS: All patients remained free of recurrence with stable visual acuities. CONCLUSIONS: Adalimumab appears to maintain disease remission in Behçet's disease.